VP, Media and Marketing Lab, Pfizer
Self-confessed “chief media nerd” Risa Wexler is on the front lines of change in the pharmaceutical industry. She uses her digital expertise to lead pharma giant Pfizer’s media practice and U.S. digital accelerator team, which has been charged with devising smarter and more engaging ways to deliver information that could benefit patients.
That, of course, is easier said than done. Wexler’s job would be daunting enough if Pfizer was the staid, old pharma giant it’s portrayed as in some circles, but the company is undergoing changes that leave it looking — and acting — much more nimble.
This summer, Pfizer agreed to buy Array BioPharma for nearly $11 billion, a deal that would see Pfizer expand its roster of cancer drugs with targeted therapies. Meanwhile, Pfizer also agreed to spin off Upjohn, its generics business, into a joint venture with Mylan; this would move Viagra and Lipitor under the same tent as EpiPen.